drugset
drugset / Trial / NCT00503477

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

NCT00503477 ↗

Phase 1 Completed 40 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase I open label dose escalation study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients in Japan with advanced solid malignancies. In addition there will be an expanded cohort multi-centre study phase with NSCLC patient and CRC patients

Timeline

Start
2005-10
Primary completion
2007-07
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule — Oral

Indications

neoplasm